A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

• Status: Recruiting
• Trial end date: 2022-09-29
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of the study is to assess the effect of LY3502970 in participants who have obesity or are overweight

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)

• Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]

• Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion Criteria:

• Have any prior diagnosis of diabetes

• Have a prior or planned surgical treatment for obesity

• Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity

• Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²

• Have a history of acute chronic pancreatitis

• Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

• Have poorly controlled hypertension

• Have history of acute myocardial infarction

• Have history of cerebrovascular accident (stroke)

• Had hospitalization due to congestive heart failure (CHF)

• Have cancer

• Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening

• Have hepatitis B and/or positive hepatitis B surface antigen